Karyopharm Therapeutics reported $46.96M in EBIT for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
AstraZeneca AZN:LN 3.32B 3.32B
Avrobio Inc AVRO:US $ -29418000 1.46M
Enanta Pharmaceuticals ENTA:US $ -33847000 3.44M
Mirati Therapeutics MRTX:US $ -184218000 12.86M
Nektar Therapeutics NKTR:US $ -112910000 686K
Novartis NOVN:VX 2.88B 596M
Sangamo Biosciences SGMO:US $ -45261000 5.36M
Tg Therapeutics TGTX:US $ -92947000 7.82M
Xencor XNCR:US $ 26.47M 65.19M